AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00507221
Drug: Praziquantel
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At enrollment and 12 months: 25mg/kg X 1
Trial: NCT03562429
Drug: TGF
RxNorm normalized name: Anti-TGF-beta 2G7
DrugBank: 2G7 (DB18589)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGF is a powder formulation of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
Trial: NCT02342145
Drug: Basiliximab,
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Basiliximab was used 10mg each time on 0d(after transplantation) and +4 d .
Trial: NCT01233609
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One to four 250mg softgels by mouth daily (dose determined by body weight)
Trial: NCT02342145
Drug: cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specifically cyclosporine A was used by intravenous drip infusion on 2mg/kg dosage from -1d and change to 5mg/kg twice oral when gastrointestinal function recovers. The blood concentrations of cyclosporine A was maintained 150-250ng/ml.
Trial: NCT03772951
Drug: Clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the course of disease is more than 2 years, the condition is stable for more than one month
Trial: NCT02342145
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil was used 0.25g qd from 0d to 3 months for prevention of graft-versus-host-disease.
Trial: NCT02400814
Drug: Anti-PD-L1 Monoclonal Antibody MPDL3280A
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02394652
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin is an antidiabetic agent given orally.
Trial: NCT02394652
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin is an antineoplastic agent given intravenously.
Trial: NCT02394652
Drug: FAZA
RxNorm normalized name: Fazaclo
DrugBank: Fazadinium bromide (DB13745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAZA is an investigational imaging agent for positron emission tomography scans indicated for hypoxia.
Trial: NCT01225913
Drug: fluticasone/salmeterol in all asthmatics
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days
Trial: NCT01046422
Drug: BMS-770767
RxNorm normalized name: BMS-770767
DrugBank: BMS-770767 (DB18902)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, 15mg, Active, Daily, 28 days
Trial: NCT01225913
Drug: budesonide/formoterol or fluticasone/salmeterol in all asthmatics
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: budesonide 160ug/formoterol 4.5ug, 2 inhalations bid or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid
Trial: NCT00003344
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01046422
Drug: BMS-770767
RxNorm normalized name: BMS-770767
DrugBank: BMS-770767 (DB18902)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, 50mg, Active, Daily, 28 days
Trial: NCT01046422
Drug: BMS-770767
RxNorm normalized name: BMS-770767
DrugBank: BMS-770767 (DB18902)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, 150mg, Active, Daily, 28 days
Trial: NCT01046422
Drug: BMS-770767
RxNorm normalized name: BMS-770767
DrugBank: BMS-770767 (DB18902)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, 50mg BID, Active, Daily, 28 days
Trial: NCT01046422
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days
Trial: NCT04197479
Drug: Resmetirom
RxNorm normalized name: Resmetirom
DrugBank: Resmetirom (DB12914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT00884416
Drug: Sorafenib dose escalation
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib dose escalation scheme: 3 first patients: 200 mg/d, if dose limiting toxicities (DLT) not reached: 3 patients at 200 mg BID, if no DLT reached: 3 patients at 400 mg bid
Trial: NCT01101061
Drug: Romosozumab
RxNorm normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered by subcutaneous injection
Trial: NCT02621255
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia type of performed for patient which has femur fracture.
Trial: NCT02033473
Drug: Apelin
RxNorm normalized name: Apelin
DrugBank: Apelin (DB18909)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An apelin clamp in which an apelin infusion will be administered
Trial: NCT01993849
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is the medication N-acetylcysteine (NAC)
Trial: NCT02621255
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia type of performed for patient which has femur fracture.
Trial: NCT01363310
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage form: tablets Day 1-2: 50 mg Day 3-7: 150 mg Day 8-57: either 150 or 300 mg/day (flexible)
Trial: NCT01363310
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage form: capsules Day 1-7: 10 mg Day 8-57: 10 or 20 mg/day (flexible)
Trial: NCT01114308
Drug: Probuphine (buprenorphine implant)
RxNorm normalized name: Probuphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
Trial: NCT01114308
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sublingual buprenorphine/naloxone tablets
Trial: NCT00002536
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002536
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00239447
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01137747
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01426113
Drug: bimatoprost ophthalmic solution formulation A
RxNorm normalized name: bimatoprost Ophthalmic Solution
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning for 6 weeks.
Trial: NCT01426113
Drug: timolol ophthalmic solution
RxNorm normalized name: timolol Ophthalmic Solution
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
Trial: NCT00296387
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00641173
Drug: paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment with SSRI paroxetine
Trial: NCT00216450
Drug: rabeprazole sodium
RxNorm normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00460148
Drug: Ropinirole
RxNorm normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01426113
Drug: bimatoprost vehicle
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 drop of bimatoprost vehicle in the affected eye(s) in the morning for 6 weeks, followed by 1 drop of bimatoprost vehicle in the affected eye(s) in the evening for 6 weeks.
Trial: NCT02472054
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02472054
Drug: Methyl Prednisolone (MP)
RxNorm normalized name: Prednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02472054
Drug: Cyclosporin A (CSA)
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00168493
Drug: antidepressants primarily selective serotonin reuptake inhibitors
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal clinical dosages used according to clinical response as determined by a psychiatrist
Trial: NCT00479219
Drug: GSI-953
RxNorm normalized name: GSI-136
DrugBank: GSI-136 (DB12819)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00532246
Drug: raloxifene
RxNorm normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03446638
Drug: FDA-approved drug or combination of drugs
RxNorm normalized name: afamelanotide
DrugBank: Afamelanotide (DB04931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients assigned to this arm will receive an FDA-approved drug or combination of drugs. Dosing and treatment schedule will follow the package insert for the selected drug(s).
Trial: NCT03446638
Drug: 7 + 3 induction
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 100-200 mg/m2 per day intravenously of cytarabine for 7 days, plus either 45-60 mg/m2 per day intravenously of daunorubicin or 9-12 mg/m2 per day intravenously of idarubicin for 3 days.
Trial: NCT03446638
Drug: Low-dose cytarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 20 mg/m2 per day subcutaneously of cytarabine for 10 days every 28 days.
Trial: NCT04751136
Drug: cerebrolysin
RxNorm normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants of the treatment group were given Cerebrolysin in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).Each selected infant, in both treatment and control group, was assessed as regard: Socioeconomic status, Nutritional status and feeding practice, assessed for neurocognitive development
Trial: NCT02722811
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: etanercept of 50 mg/w, subcutaneous injection; treatment: 8 weeks
Trial: NCT01398098
Drug: Sodium phosphate
RxNorm normalized name: Sodium Phosphate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 32 tablets
Trial: NCT00001509
Drug: IFN-alpha with retinoic acid
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04138342
Drug: Quantum dots coated with veldoreotide
RxNorm normalized name: D3 Dots
DrugBank: Veldoreotide (DB12777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active group will receive Quantum dots coated with veldoreotide in different topical dosage forms as an anti-cancer drug.
Trial: NCT03713320
Drug: Cobomarsen
RxNorm normalized name: Cobomarsen
DrugBank: Cobomarsen (DB14931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At least weekly doses of cobomarsen (282 mg) throughout study treatment period
Trial: NCT03713320
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily doses of vorinostat throughout study treatment period
Trial: NCT00433875
Drug: AMG 714
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02271230
Drug: Vitamin D and fish oil
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU vitamin D and 1g/d fish oil
Trial: NCT04026945
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release lidocaine injection
Trial: NCT01099579
Drug: Atazanavir powder
RxNorm normalized name: atazanavir Oral Powder
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Powder, oral, dosed by weight. Participants who weighed 5 to \<10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to \<15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to \<25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
Trial: NCT01099579
Drug: Ritonavir oral solution
RxNorm normalized name: Ritonavir Oral Solution
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
Trial: NCT01099579
Drug: Atazanavir capsules
RxNorm normalized name: Atazanavir Capsules
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, oral, dosed by weight in Stage 2. Patients who reached the age of 6 years or a weight of ≥25 kg transitioned from the powder to the capsule formulation of atazanavir (ATV). Patients who weighed 15 to \<20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to \<40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
Trial: NCT01099579
Drug: Ritonavir capsules
RxNorm normalized name: Ritonavir Capsules
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral, capsules, 100 mg, administered in Stage 2 with atazanavir capsules, dosed by weight.
Trial: NCT00503503
Drug: Enbrel (etanercept)
RxNorm normalized name: etanercept Cartridge [Enbrel]
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02489409
Drug: EndostarTM Injection
RxNorm normalized name: Endostar
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h)
Trial: NCT02489409
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.0 m/m2, iv 0.5h, d1, 8
Trial: NCT02489409
Drug: Navelbine
RxNorm normalized name: Navelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/d, iv, d1, 8
Trial: NCT02489409
Drug: Platinum
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2, iv 3h, d1-3
Trial: NCT00020722
Drug: Ifosfamide, carboplatin, and etoposide (ICE) regimen
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ifosfamide 2,500 mg/m2 given IV daily on day -8, -7, -6, -5, -4, and -3 prior to PBSCT. Ifosfamide 2,500 mg/m2 infused IV over 1 hour (hour 0-1) on days -8 to -3 for a total dose of 15,000 mg/m2.~Mesna will be administered per BMT Standard of Care Guideline at a dose of 25% of the total Ifosfamide dose 30 minutes prior to and then 3, 6, and 9 hours after ifosfamide daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 2500 mg/m2.~Carboplatin at a dose of 250 mg/m2 will be given daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 1500 mg/m2.~VP-16 (etoposide) at a dose of 200 mg/m2 will be given IV on days -8, -7, -6, -5, -4 and -3. The total dose of VP-16 given prior to PBSCT will be 2,400 mg/m2. VP-16 will be given 200 mg/m2
Trial: NCT03363659
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide is taken once daily
Trial: NCT04543812
Drug: Ferric citrate
RxNorm normalized name: Ferric Citrate
DrugBank: Ferric sulfate (DB11171)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric citrate will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
Trial: NCT01130168
Drug: Comparator: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks
Trial: NCT02087215
Drug: boron gel
DrugBank: Boron (DB11203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: application of a formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v) to diabetic foot ulcers.
Trial: NCT01688960
Drug: nesvacumab (REGN910/ SAR307746)
RxNorm normalized name: Nesvacumab
DrugBank: Nesvacumab (DB15330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 1
Trial: NCT01688960
Drug: nesvacumab (REGN910/ SAR307746)
RxNorm normalized name: Nesvacumab
DrugBank: Nesvacumab (DB15330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 2
Trial: NCT01688960
Drug: nesvacumab (REGN910/ SAR307746)
RxNorm normalized name: Nesvacumab
DrugBank: Nesvacumab (DB15330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 3
Trial: NCT01688960
Drug: aflibercept (ziv-aflibercept)
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose level 1
Trial: NCT01688960
Drug: aflibercept (ziv-aflibercept)
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose level 2
Trial: NCT00166881
Drug: Docetaxel-Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Docetaxel-Irinotecan, weekly, days 1, 8, 15, repeated every 4 weeks
Trial: NCT02900235
Drug: MT-3995
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04642547
Drug: Lenvatinib and Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First week: Gefitinib: 125mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral.~One week later: Gefitinib: 250mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral.
Trial: NCT02635386
Drug: Exenatide once weekly (EQW )
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg SC injection every 7 days
Trial: NCT02635386
Drug: Dapagliflozin (DAPA)
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One pill (10 mg) by mouth daily (QD) in am
Trial: NCT02635386
Drug: Dapagliflozin plus Glucophage (MET ER)
RxNorm normalized name: metformin Extended Release Oral Tablet [Glucophage]
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose
Trial: NCT02635386
Drug: Phentermine /Topiramate (PHEN/ TPM) ER
DrugBank: Phentermine (DB00191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am
Trial: NCT01216293
Drug: Dexlansoprazole
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole 60 mg capsules
Trial: NCT01216293
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg capsules
Trial: NCT01222221
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01080651
Drug: Voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day1: voriconazole 200 mg x 2, oral administration, Day2-7: rifampin 600 mg, once a day oral administration, Day8: voriconazole 200 mg x 2 + rifampin 600 mg, oral co-administration
Trial: NCT00216762
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituxan ® 1000 mg IV x 2 infusions, 2 weeks apart
Trial: NCT04171349
Drug: Articaine
RxNorm normalized name: Articaine
DrugBank: Articaine (DB09009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vial
Trial: NCT04171349
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vial
Trial: NCT01062269
Drug: Cholestyramine
RxNorm normalized name: Cholestyramine
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cholestyramine 4 grams one time dose
Trial: NCT01062269
Drug: Cholestyramine
RxNorm normalized name: Cholestyramine
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cholestyramine 12 grams one dose, one day